{'fraction_non_alphanumeric': 0.044813278008298756, 'fraction_numerical': 0.03983402489626556, 'mean_word_length': 4.4818181818181815, 'pattern_counts': {'":': 0, '<': 3, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Anti-diabetic activity of Emblica officinalis in animal models

The aqueous extract of Emblica officinalis Gaertn. (syn: Phyllanthus emblica L.) (Euphorbiaceae) seeds was investigated for its anti-diabetic activity in animal models. Streptozotocin (STZ)-induced type 2 diabetes models were used for the study. The standardized doses of 100, 200, 300, and 400 mg kg−1 body weight of the extract were administered orally to normal and diabetic rats in order to define its glycemic potential. The maximum fall of 27.3% (p < 0.001) in the blood glucose level of normal rats was observed at 6 h during fasting blood glucose studies, with the dose of 300 mg kg−1 identified as the most effective dose. The same dose produced a fall of 25.3% (p < 0.001) in the same models during the glucose tolerance test (GTT) at 3 h after glucose administration. However, the dose of 300 mg kg−1 of aqueous seed extract in sub- and mild-diabetic animals produced a maximum fall of 34.1 and 41.6% (p < 0.01), respectively, during the GTT at 3 h after glucose administration. This evidence clearly indicates that the aqueous extract of E. officinalis seeds has definite hypoglycemic potential as well as anti-diabetic activity.